↑ Rising
Business
🔮 fades ✗
Alzheimer's: Real-world study confirms Leqembi therapy benefits
The FDA has approved a subcutaneous, at-home initiation dose of Leqembi for patients with early Alzheimer's disease.
1 trends tracked about this subject — the full history, oldest to newest below.
The FDA has approved a subcutaneous, at-home initiation dose of Leqembi for patients with early Alzheimer's disease.